Compare · EXAI vs MRNA
EXAI vs MRNA
Side-by-side comparison of Exscientia Plc (EXAI) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXAI and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $21.45B.
- MRNA has hit the wire 10 times in the past 4 weeks while EXAI has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 2 for EXAI).
- Company
- Exscientia Plc
- Moderna Inc.
- Price
- -
- -
- Market cap
- -
- $21.45B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 0
- 10
- Recent ratings
- 2
- 25
Exscientia Plc
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest EXAI
- SEC Form 15-12G filed by Exscientia Plc
- Amendment: SEC Form SC 13G/A filed by Exscientia Plc
- Amendment: SEC Form SC 13D/A filed by Exscientia Plc
- SEC Form S-8 POS filed by Exscientia Plc
- SEC Form S-8 POS filed by Exscientia Plc
- SEC Form 6-K filed by Exscientia Plc
- SEC Form 25-NSE filed by Exscientia Plc
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- SEC Form 6-K filed by Exscientia Plc
- Recursion and Exscientia Shareholders Approve the Proposed Combination
Latest MRNA
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax